Abstract 2104P
Background
Common side effects of taxanes are nail toxicity (tox) and CIPN. Different methods of cryotherapy to prevent these side effects have been tested. We investigated machine-controlled cooling of hand and feet to reduce nail tox and CIPN.
Methods
Patients (pts) receiving Docetaxel (Doce) (planned dose 300mg/m2) or Paclitaxel (Pacli) (planned dose 720mg/m) in the adjuvant or palliative setting were included. The dominant hand and foot were cooled to approximately 10°C using the Hilotherapy-machine. The contralateral hand and foot were used as intrapatient comparison. Primary endpoint was the occurrence of any nail tox (Doce cohort) or CIPN (Pacli cohort) at any time during and up to 56 days after the end of treatment. We assumed an absolute improvement of 40% in nail tox and 20% in CIPN. With 90% power using a two-sided McNemar test with a significance level of 5%, a total of 30 pts were needed in each group. The intended to treat population (ITT) and the per protocol population (PPP) were analysed. Toxicity was assessed using the CTCAE v5.0 grading system and the PNQ questionnaire.
Results
69 pts, 21 (9 in the PPP) treated with Doce and 48 (34 in the PPP) treated with Pacli, were included from 08/2020 - 08/2022. In the Doce cohort, nail tox was not significantly improved by cooling in the ITT (81.0%, vs 85.7%; odds ratio (OR) 0.71, 95% CI: 0.14 – 3.64, p = 0.564) and PPP (100% vs 100%; OR: 1.00, 95% CI: 0.00 – NA, p = NA) but significant benefit across visits over time was found for the ITT (OR: 0.42, 95% CI: 0.18 – 0.98, p=0.045) but not the PPP (OR: 0.75, 95% CI: 0.30 – 1.86, p=0.529). In the Pacli cohort, CIPN was numerically better in the ITT (60.9% vs. 71.7%, OR: 0.61, 95% CI: 0.26 – 1.47, p=0.059) and significantly better in the PPP (67.6% vs. 82.4%, OR: 0.45, 95% CI: 0.14 – 1.40, p-value = 0.025). Differences across visits were significantly in favour of cooling (ITT: OR: 0.28, 95% CI: 0.13 - 0.57, p=0.001; PPP: OR: 0.25, 95% CI: 0.12 - 0.55, p=0.001). Cooling was well tolerated, only 6 pts (9%) discontinued due to side effects.
Conclusions
Cooling of hand and feet has a clinically meaningful impact on occurrence of CIPN and nail toxicity. Effects are more significant over time and are taxane dose dependent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kantonsspital Graubünden, Chur, Switzerland.
Funding
Has not received any funding.
Disclosure
R. Cathomas: Financial Interests, Institutional, Advisory Board: AstraZeneca, BMS, Bayer, MSD, Roche, Sanofi, Astellas, Ipsen, Merck, Pfizer, Debiopharm; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Invited Speaker: Janssen, Merck; Financial Interests, Institutional, Invited Speaker: Astellas; Non-Financial Interests, Member of Board of Directors: SAKK Swiss Working Group for Clinical Cancer Research. All other authors have declared no conflicts of interest.
Resources from the same session
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06